The support of the Life Ring Foundation makes possible testing of a new drug combination for relapsed and refractory hepatoblastoma. This combination of the polo-like kinase inhibitor Onvansertib with the chemotherapy drug irinotecan has had favorable results in a mouse model of one child’s cancer. The question is: how many children might this combination apply to? By testing additional children’s cancers, we can decide if a national clinical trial is merited.